Despite the recent advances in the clinical management of melanoma, there remains a need for new pharmacological approaches to treat this cancer. 2-methoxyestradiol (2ME) is a metabolite of estrogen that has shown anti-tumor effects in many cancer types. In this study we show that 2ME treatment leads to growth inhibition in melanoma cells, an effect associated with entry into senescence, decreased pRb and Cyclin B1 expression, increased p21/Cip1 expression and G2/M cell cycle arrest. 2ME treatment also inhibits melanoma cell growth in colony formation assay, including cell lines with acquired resistance to BRAF and BRAF + MEK inhibitors. We further show that 2ME is effective against melanoma with different BRAF and NRAS mutational status. Moreover, 2ME induced the retraction of cytoplasmic projections in a 3D spheroid model and significantly decreased cell proliferation in a 3D skin reconstruct model. Together our studies bring new insights into the mechanism of action of 2ME allowing melanoma targeted therapy to be further refined. Continued progress in this area is expected to lead to improved anti-cancer treatments and the development of new and more effective clinical analogues.
Introduction
Melanoma incidence continues to increase year-on-year and is currently responsible for >80% of deaths from skin cancer [1] . Melanomas are known to have the highest mutational load of all cancers. Among these, activating mutations in the serinethreonine kinase BRAF are the most prevalent and lead to the constitutive activation of the Ras-mitogen-activated protein kinase (MAPK) pathway [2] . A number of small molecule inhibitors, including vemurafenib and dabrafenib, are successful at treating BRAF mutant melanoma, albeit for only limited periods of time [3] [4] [5] . Indeed, long-term treatment has showed that the tumors often become resistant to such inhibitors [3, 4] . Acquired BRAF inhibitor resistance is known to be mediated through several mechanisms with reactivation of the RAF-MEK-ERK signaling pathway being the most prevalent in >70% of cases. Increased RAF-MEK-ERK signal-ing can occur secondary to many events including the acquisition of NRAS mutations, mutations in MEK1/2, BRAF-splice mutants and through increased receptor tyrosine kinase signaling [6] . Thus, despite the advances in the melanoma treatment, there is still an urgent need to identify new therapeutic strategies.
D'Amato and collaborators demonstrated the potential activity of 2-methoxyestradiol (2ME), a natural metabolite of the endogenous estrogen hormone 17-␤estradiol, to hinder angiogenesis through inhibition of tubulin polymerization [7] . Moreover, Fotsis and collaborators revealed the high cytotoxicity of 2ME in vascular endothelial cells leading to inhibition of tumor angiogenesis and growth in vivo [8] . Multiple in vitro and in vivo studies have shown the potential of 2ME to induce cell death and inhibit angiogenesis across many different tumor types [9] [10] [11] [12] [13] . In melanoma, the antitumor effect of 2ME has been little explored. To date, one study has reported 2ME to induce G2/M phase cell cycle arrest and apoptosis in a human melanoma cell line [13] . In another study, using eight different human melanoma cell lines, 2ME promoted apoptotic cell death by activation of the intrinsic pathway and blockage of cell cycle progression in vitro, as well as regression of the primary and metastatic tumors in vivo [14] . 2ME has completed Phase I/II clinical trials for single-drug treatment of breast, renal, prostate, multiple myeloma and glioblas-toma multiforme tumors (Clinicaltrials.gov − NCT00030095; NCT00444314; NCT00394810; NCT00592579; NCT00306618) and was associated with few side effects [15] . In combination with other drugs, such as temozolomide (an alkylating agent) and sunitinib (a multi-targeted tyrosine kinase inhibitor), 2ME caused significant decrease in tumor growth (Clinicaltrials.gov − NCT00481455; NCT00444314). Overall, systemic toxicity was low and there was evidence of efficacy [16] [17] [18] . In lights of these results, and the need for new drugs with anti-melanoma activity, we undertook testing of this compound in different melanoma cell lines harboring multiple mutation profiles, as well as in BRAF inhibitor (BRAFi) and BRAF + MEK inhibitor (BRAFi + MEKi) resistant cell lines. We demonstrated that 2ME is anti-proliferative and induces cell death in 2D and 3D in vitro models. Moreover, 2ME was able to inhibit colony formation and decrease the number of cellular projections in melanoma cells with acquired resistance to BRAFi and BRAFi + MEKi. Thus, 2ME has promising anti-melanoma activity that is worthy of further exploration.
Material and methods

Cell culture
The melanoma cell lines SK-Mel-28, SK-Mel-103, SK-Mel-147, M245, WM1361A and WM1366 were kindly donated by Dr. Maria S. Soengas (Melanoma Group, CNIO, Spain). Primary cultures of fibroblasts were obtained from the foreskins of University Hospital (Hospital Universitário − HU-USP) patients, provided by Dr. Linda Maximiano. To this end, the project has undergone review and approval by the Ethics Committee of HU-USP (CEP Case 943/09). Melanoma cells and fibroblasts were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 U/ml penicillin and 50 g/mL streptomycin. All cells were maintained at 37 • C under 5% CO 2 atmosphere.
Proliferation assay
Cells were seeded in 96-well plates with 2.5 × 10 3 cells in 100 L medium per well overnight before treatment with increasing concentrations of 2ME. Metabolic activity was assayed after incubation with 2ME for 72 h, using Alamar Blue reagent according to the manufacturer's protocol (Invitrogen, Carlsbad, CA, USA) [19] .
Clonogenic assay
Cells were seeded on 6-well plates (5 × 10 3 ) and cultured for 24 h. After that, cells were treated with 0.0 or 0.5 M of 2ME and maintained in culture for 14 days. The medium and treatment were replaced three times every week. Cells were further stained with crystal violet (0.5% w/v) for colonies counting.
Senescence-associated ˇ-Galactosidase (SA-ˇgal)
Cells were seeded in six-well plates (5 × 10 4 ) and, after 24 h, treated with 0.0 or 1.0 M of 2ME. After fixation, SA-␤gal cytochemical detection was performed according to Debacq-Chainiaux and collaborators [20] . Plates were further incubated overnight at 37 • C. Blue stained cells were detected under a bright-field microscope for senescence evaluation.
Protein expression by western blotting
Proteins were extracted and blotted (30 g) as described by Faião-Flores and collaborators (2016) [21] . After analysis, Western Blottings were stripped once and reprobed for ␤-actin or GAPDH to show even protein loading. Antibodies to phosphorylated RB S807/811, total RB, Parp, Caspase-9, Caspase-7, Bcl-2, H3K9me3 and Cyclin B1 were purchased from Cell Signaling Technology (Beverly, MA, USA). The monoclonal antibodies to ␤-actin and GAPDH were purchased from Sigma (St. Louis, MO, USA). Monoclonal antibody to p21 was purchased from BD Biosciences (Franklin Lakes, NJ, USA).
Cell cycle analysis by flow cytometry
Cells were seeded on 6-well plates (5 × 10 5 ) and cultured for 24 h. After that, cells were treated with 0.0, 0.5, 1.0 or 10.0 M of 2ME for 24 or 48 h. Then, cells were collected and pellets were washed with cold PBS. The cells were further incubated with propidium iodide (50 g/mL) and 0.1% triton x-100 for 30 min followed by flow cytometry analysis (FACSCantoBeckton Dickson, CA, USA).
Apoptosis analysis by flow cytometry
After treatment with 2ME (0-10 M) for 5 days, cells were washed once with Annexin binding buffer [10 mmol/L HEPES (pH 7.4), 140 mmol/L NaCl, 5 mmol/L CaCl 2 ], resuspended in 100 L binding buffer containing 1 L APC-conjugated Annexin V (R&D Systems, Minneapolis, MN, USA), and incubated at 37 • C for 15 min. Cells were then analyzed for Annexin V green fluorescence using flow cytometry.
Three-Dimensional (3D) spheroid growth
Melanoma spheroids were prepared using the liquid overlay method. Briefly, 200 L of melanoma cells (25,000/mL) were added to a 96-well plate coated with 1.5% agar (Difco, Sparks, MD, USA). Plates were incubated for 72 h, by which time cells had organized into 3D spheroids. Spheroids were then harvested and implanted into a bovine collagen I gel containing EMEM, L-glutamine, and 2% fetal bovine serum. Normal 2% melanoma medium was overlaid on top of the solidified collagen. Spheroids were treated with 5.0 M of 2ME for 5 days. Spheroids were then washed twice in PBS before being treated with calcein-AM and ethidium bromide (Molecular Probes, Eugene, OR, USA) for 1 h at 37 • C according to the manufacturer's instructions. After this time, pictures of the invading spheroids were taken using a Nikon-300 inverted fluorescence microscope. Calcein and ethidium bromide staining were used as a live/dead cell marker, respectively. The images were imported to Definiens Tissue Studio v4.1 software to analyze the fluorescence as described by Sandri et al. (2016) [22] and the ratio was determined by live fluorescence divided by dead fluorescence.
Human skin reconstructs containing melanoma cells
The skin model was reconstructed based on the previous description by Sandri and collaborators (2016) with minor changes [22] . The SK-Mel-28 melanoma cells were incorporated into the epidermis at the same time as keratinocytes and melanocytes. After 24 h of submersion, the skin samples were transferred to the air-liquid interface and maintained for two weeks in culture medium composed of DMEM/HAM's F-12 supplemented with 10% FBS. Then, the reconstructed skin was treated with 5.0 M of 2ME for 72 h, followed by fixation with 4% paraformaldehyde solution and permeabilization with 0.2% Triton X-100 prior to blockage with 1% BSA/PBS. The samples were incubated with hematoxylin/eosin (HE) for histology or primary antibodies (Laminin and Filagrin) for immunofluorescence overnight at 4 • C. On the next day, the immunohistochemistry samples were incubated with secondary antibodies for 1 h at room temperature and washed with PBS. The coverslips were mounted with ProLong Gold antifade reagent with DAPI (Life Technologies, Carlsbad, CA, USA) and imaged using fluorescence microscopy. 
Statistical analysis
*Data show the mean of at least 3 independent experiments. GraphPad Prism 5 statistical software was used to perform the Student's t-test for comparison of treatment effects in the different culture conditions. Results were considered statistically significant when where (*) indicates p ≤ 0.05, (**) indicates 0.05≤ P ≤ 0.01, (***) indicates P ≤ 0.001. Ns indicates non-significant.
Results
2ME induces inhibition of proliferation in melanoma cells
Experiments were carried out to compare the growth rate of melanoma cells under different concentrations of 2ME (0.0, 0.5 and 1.0 M). As observed in Fig. 1A , cell growth was significantly decreased starting from 0.5 M for SK-Mel-103 and SK-Mel-147 cell lines (NRAS mutated), and starting from 1.0 M for SK-Mel-28 cell line (BRAF mutated). To calculate the 50% inhibitory concentration (IC 50 ) of 2ME, cells were incubated for 72 h with 2ME at concentrations ranging from 0.01 to 30 M, as shown in Fig. 1B . Interestingly, NRAS mutated SK-Mel-103 and SK-Mel-147 cell lines were more sensitive to 2ME effects, and had IC 50 values below 1 M.
We then evaluated the effects of 2ME in the melanoma cell lines in long-term colony formation assays using skin fibroblasts as a control normal cell line. These results showed that 2ME treatment at 0.5 M promoted a decrease in colony formation in all the melanoma cell lines studied, but not in the normal, nontransformed cells (Fig. 1C) . We also evaluated the effects of 2ME in BRAFi (vemurafenib) resistant (R) and BRAFi + MEKi (vemurafenib + trametinib) resistant (RT) melanoma cell lines, obtained by chronic exposure to the respective inhibitors and found that the resistant cell lines also showed sensitivity to 0.5 M of 2ME (Supplementary Fig. 1 ). Senescence phenotype and cell cycle arrest are induced by 2ME in melanoma cell lines
We next turned our attention to the mechanisms associated with 2-ME-mediated growth inhibition and began by evaluating potential entry into a senescence-like state [23] . It was found that 2ME (1.0 M) induced senescence as shown by increased senescence associated Beta-galactosidase (SA-␤gal) blue staining after 5 days of culture ( Fig. 2A) . Treatment of the SK-Mel-28, SK-Mel-103 and SK-Mel-147 with their IC50 value of 2ME showed a higher percentage of SA-␤gal staining compared to the control group (Supplementary Table 1 ). Expression of the senescence marker Histone H3 trimethylated in the Lysine 9 (H3K9Me3), also showed a slight increase following treatment of the cells with 10 M of 2ME for 72 h (Fig. 2B) .
In cell cycle analysis studies, a 24 h treatment with the IC 50 and 10.0 M of 2ME, led to a G2/M phase cell cycle arrest in SK-Mel-28, SK-Mel-103 and SK-Mel-147 cell lines (Fig. 2C) . The same effect was not observed at 0.5 M and 1.0 M in this acute exposure. We next investigated the effects of 2ME upon the expression of a series of important cell cycle proteins by Western Blotting. In these studies we treated SK-Mel-28 and SK-Mel-103 cell lines with 0.5 and 1.0 M of 2ME for 5 days (Fig. 2D) . It was found that phos- Western Blotting analysis of pro-and anti-apoptotic proteins after treatment with 2ME for 3 days. GAPDH was used as a loading control. Experiments were performed in triplicates. Values are expressed as mean ± s.d. Significance is indicated by *P < 0.05, **P < 0.01 and ***P < 0.001. Ns indicates non-significant. phorylation of the Rb protein at serine 807 and 811 (pRb) were down-regulated in both cell lines. pRb is required for the exit of the G0 phase of the cell cycle, and its phosphorylation is enhanced by Cyclin C expression [24] , hence, inhibition of pRb S807/811 is associated with cell cycle arrest. Additionally, p21 Cip1 , an inhibitor of the CDK/Cyclin complex, was also up-regulated in the presence of 2ME. Furthermore, Cyclin B1 also showed an up-regulation. The coordinated change in all of these cell cycle proteins is likely to underlie the effects of 2ME upon cell proliferation. To further investigate the molecular mechanisms underlying the inhibition of proliferation, we examined the potential effects of 2ME upon pERK signaling by Western Blotting. After treatment with 1.0 M of 2ME (1 h −72 h), no alteration of ERK phosphorylation status was observed. These results suggest that the inhibition of proliferation is not due to direct inhibition of the MAPK signaling ( Supplementary   Fig. 2 ). This led us to hypothesize that inhibition of the MAPK pathway in combination with 2ME would further inhibit cell growth and proliferation, leading to more effective tumor growth inhibition.
2ME induces the apoptotic pathway in melanoma cell lines
Next we assessed apoptosis induction through detection of Annexin V positive cells by flow cytometry. 2ME induced significant levels of apoptotic cell death starting at a concentration of 1.0 M in SK-Mel-28 and SK-Mel-103 cells, and from 0.5 M in SK-Mel-147 cell line (Fig. 3A) . It was additionally found that 2ME treatment increased expression of cleaved PARP, caspase-9 and caspase-7 in all of the cell lines after 5 days of treatment, especially at the 1 M. The anti-apoptotic protein Bcl-2 was downregulated after 2ME treatment only in the SK-Mel-147 cell line, showing that, although apoptosis is induced across cell lines, the mechanism of induction may be cell type-dependent (Fig. 3B) .
Invasion decreases after 2ME treatment in 3D models
To test the effects of 2ME in a model more analogous to the in vivo 3D tumor environment, we next performed a serie of 3D spheroid assays. The results showed that 2ME induced cell death as indicated by an increase in red fluorescence showing 25% and 16% of decrease in live/dead ratio in SK-Mel-28 and SK-Mel-103 melanoma cell lines (Fig. 4A) . In addition, we noted a retraction of melanoma cell cytoplasmic projections from the spheroids after 2ME treatment, possibly indicating anti-metastatic activity. The growth inhibition and the increase in cell death were also observed in SK-Mel-28RT cells, which are resistant to BRAFi + MEKi therapy ( Supplementary Fig. 3) , showing that, even in a 3D model, 2ME was able to overcome acquired resistance to targeted kinase inhibitors.
These effects were further confirmed in the 3D artificial skin model with melanoma cells, as previously described [21, 22, 25] . Untreated skin reconstructs were marked by melanoma invasion and/or migration through the basal membrane into the dermis, which is visible in both HE staining and fluorescence microscopy; invading melanoma cells nuclei are stained in blue by DAPI, below the basal membrane, and are shown in green by Laminin immunofluorescence. After 2ME treatment, the melanoma cells in this model showed significant decrease in proliferation as indicated by the lower DAPI staining. Furthermore, treated cells were scarcely detected in the dermis, indicating lower invasion/migration (Fig. 4B) . 5 nM) and/or 2ME (500 nM) for 72 h. (B) Cell viability proportion normalized to 100% for each condition after treatment with BRAFi (250 nM), MEKi (2.5 nM) and/or 2ME (500 nM) for 72 h. Experiments were performed in triplicates. Values are expressed as mean ± s.d. Significance is indicated by *P < 0.05, **P < 0.01 and ***P < 0.001. Ns indicates non-significant.
The combination of BRAFi, MEKi and 2ME shows additive effect on naïve cells
When used as a monotherapy, BRAFi, MEKi and 2ME showed 70.8, 80.4 and 31.6% of cell proliferation, respectively, after 72 h (Fig. 5A) . While 2ME showed relatively lower potential in inhibition of cell proliferation, it induced more cell death (Fig. 5B) . Moreover, MEKi treatment combined with either BRAFi or 2ME was associated with a significantly higher cell death ratio (81.3 and 78.7%, respectively) in comparison to BRAFi, MEKi and 2ME monotherapies (26.7, 47.9 and 58.4%, respectively). Together, these three agents inhibited cell proliferation by >80% and led to an induction of cell death in >94% of the cells.
Discussion
In the present work we showed 2ME to have antiproliferative and cytotoxic effects in 2D and 3D human melanoma cell culture models. 2ME is a metabolite of estrogen and has antitumoral activity against many cancer cells, such as lung cancer [9] , ovarian cancer [10] , hepatocellular carcinoma [11] , colon cancer [12] and melanoma [13] . Herein, 2ME affected melanoma cell lines with different genetic backgrounds, confirming that its effects are independent of BRAF and NRAS mutational status. It was shown for the first time that this drug has anti-mitotic and cytotoxic effects on BRAF V600E mutant melanoma cell lines that are resistant not only to BRAFi (Vemurafenib) but also to the BRAFi + MEKi combination.
Previous work in the field has shown that 2ME presents antiproliferative effects in melanoma, but the mechanisms involved remain poorly understood. The first related study published by Ghosh and collaborators revealed the selective antiproliferative effect of 2ME against melanoma cell lines, while but not against non-tumorigenic fibroblasts [13] . In addition, Dobos and collaborators showed proliferation inhibition, induction of apoptosis and alterations in tubulin polymerization in human melanoma [14] . Different reviews on microtubule-targeting agents (MAT) cite 2ME as an anti-cancer agent that acts through impairment of tubulin polymerization by interaction with the colchicine site on ␤-tubulin subunit [26, 27] .
In our study, we found that, in addition to the effects of 2ME upon tubulin polymerization (data not shown), there were other effects that led to the inhibition of proliferation. Of note, 2ME was found to induce senescence in all the melanoma cell lines tested. The senescence phenotype was more pronounced in the SK-Mel-103 and SK-Mel-147 cell lines, an effect associated with enhanced SA-␤gal staining and a higher level of H3K9me3 expression. The expression of SA-␤gal is the most widely used readout of senescence induction [28] . Moreover, H3K9me3 expression is related to cell cycle arrest by local transcription repression of E2F-complexed retinoblastoma protein [29] .
Despite showing anti-mitotic effect, the specific mechanisms of 2ME upon the cell cycle have not been previously reported in melanoma. 2ME is known to induce cell cycle arrest in G2/M phase in different tumors, i.e., osteosarcoma [30] , esophageal carcinoma [31] , prostate cancer [32] , human endometrial cells [33] and melanoma [14] . Correspondingly, we found that 2ME blocked cell cycle progression in melanoma cells, which was associated with dose-dependent upregulation of p21 Cip1 , inhibition of pRB phosphorylation (S807/S811) and inhibition of Cyclin B1 expression. It is likely that the combined modulation of all of these proteins leads to cell cycle arrest and inhibition of proliferation in these cells.
As previously described by other authors investigating gastric carcinoma [34] , prostate cancer [35] and melanoma cells [13, 14] , 2ME induced apoptosis in all melanoma cell lines evaluated herein, which was demonstrated by flow cytometric analysis of Annexin V staining and confirmed by Western Blotting analysis of caspase and PARP cleavage. The induction of cell death was also observed in a 3D spheroid melanoma model after treatment with 2ME. Moreover, in this 3D model, we could observe inhibition of spheroid size and a decrease of invasion/migration potential by reduction of cellular projections. Likewise, invasive potential was modulated in a 3D reconstructed skin model as noted by the decrease in invasion/migration of melanoma cells into the dermis. Such modulation might be explained by the known antimitogenic and antimetastatic effects of 2ME [36] .
Here we demonstrated that 2ME has multiple anti-tumorigenic properties in melanoma cells including the inhibition of proliferative capability, induction of cell cycle arrest and inhibition of invasive potential. Despite research advances, 2ME has limited biological accessibility and fast metabolic breakdown [37, 38] . For this reason, many 2ME analogues have been developed and are currently undergoing preclinical evaluation [26, [38] [39] [40] [41] [42] . Satisfactorily, these analogues have shown an increased bioavailability [43] , while retaining their important mechanisms of action such as microtubule targeting, leading to proliferation inhibition and apoptosis induction of tumor cells [26] .
In conclusion, we have shown for the first time that 2ME modulates cell cycle proteins leading to cell cycle arrest and induces senescence in melanoma cells. Interestingly, it was shown that such mechanisms were independent of BRAF or NRAS mutational status, since 2ME led to the same effects on colony inhibition in wild-type and mutant cells. Furthermore, inhibition of colonies formation and reduction of spheroids in resistant cells demonstrate that 2ME treatment can overcome BRAFi and BRAFi + MEKi resistance in melanomas. In view of its promising results in melanoma cells, it is of major importance to further understand the 2ME basic mechanisms of action. Progress in this area should allow us to improve melanoma treatment, through the development of new drug combinations that lead to improved clinical outcomes.
